Denali Therapeutics Inc. (DNLI) and NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) Contrasting side by side

Both Denali Therapeutics Inc. (NASDAQ:DNLI) and NovaBay Pharmaceuticals Inc. (NYSEAMERICAN:NBY) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics Inc. 16 0.00 49.72M -0.56 0.00
NovaBay Pharmaceuticals Inc. 1 0.00 12.40M -0.50 0.00

In table 1 we can see Denali Therapeutics Inc. and NovaBay Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Denali Therapeutics Inc. 311,919,698.87% -10.2% -8.4%
NovaBay Pharmaceuticals Inc. 2,074,619,374.27% -175.4% -83.4%


The Current Ratio of Denali Therapeutics Inc. is 11.6 while its Quick Ratio stands at 11.6. The Current Ratio of rival NovaBay Pharmaceuticals Inc. is 1.3 and its Quick Ratio is has 1.2. Denali Therapeutics Inc. is better equipped to clear short and long-term obligations than NovaBay Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for Denali Therapeutics Inc. and NovaBay Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Denali Therapeutics Inc. 0 1 3 2.75
NovaBay Pharmaceuticals Inc. 0 0 0 0.00

$28 is Denali Therapeutics Inc.’s average target price while its potential upside is 54.19%.

Institutional and Insider Ownership

Institutional investors held 84.5% of Denali Therapeutics Inc. shares and 1.1% of NovaBay Pharmaceuticals Inc. shares. Denali Therapeutics Inc.’s share held by insiders are 0.1%. On the other hand, insiders held about 55.2% of NovaBay Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Denali Therapeutics Inc. 3.14% 2.59% -10.33% 12.96% 71.35% 3.34%
NovaBay Pharmaceuticals Inc. 18.58% -22.54% 36.04% -29.84% -40.44% 73.42%

For the past year Denali Therapeutics Inc. was less bullish than NovaBay Pharmaceuticals Inc.


On 6 of the 10 factors Denali Therapeutics Inc. beats NovaBay Pharmaceuticals Inc.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.